Geneos Wealth Management’s Intellia Therapeutics NTLA Stock Holding History

Geneos Wealth Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-270	Closed	-$14K	–	2397
2022 Q2	$14K	Buy	270 +20	+8%	+$1.02K	﹤0.01%	1838
2022 Q1	$18K	Sell	250 -917	-79%	-$77.7K	﹤0.01%	1860
2021 Q4	$137K	Hold	1,167	–	–	0.01%	1050
2021 Q3	$156K	Hold	1,167	–	–	0.01%	967
2021 Q2	$191K	Buy	1,167 +250	+27%	+$19.5K	0.01%	866
2021 Q1	$70K	Hold	917	–	–	﹤0.01%	1455
2020 Q4	$73K	Sell	917 -2	-0.2%	-$73	﹤0.01%	1270
2020 Q3	$19K	Buy	919 +2	+0.2%	+$42	﹤0.01%	1676
2020 Q2	$18K	Hold	917	–	–	﹤0.01%	1668
2020 Q1	$10K	Buy	+917	New	+$12.4K	﹤0.01%	1821
2019 Q4	–	Sell	-917	Closed	-$12K	–	2566
2019 Q3	$12K	Hold	917	–	–	﹤0.01%	1808
2019 Q2	$15K	Hold	917	–	–	﹤0.01%	1766
2019 Q1	$15K	Hold	917	–	–	﹤0.01%	1700
2018 Q4	$11K	Buy	+917	New	+$17K	﹤0.01%	1753

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geneos Wealth Management's NTLA Position: Q3 2022 in Review

Geneos Wealth Management sold out of Intellia Therapeutics (NTLA) in Q3 2022, closing a stake of 270 shares — an estimated $14K sold.

Geneos Wealth Management first reported a position in NTLA in Q4 2018 and held it in 14 quarters. The position peaked at $191K in Q2 2021. 319 funds tracked by Wall St. Rank hold NTLA as of Q3 2022.

Geneos Wealth Management reported no remaining Intellia Therapeutics position as of Q3 2022 after selling out during the quarter.
Geneos Wealth Management sold 270 Intellia Therapeutics shares in Q3 2022, an estimated $14K.
Geneos Wealth Management first reported a position in Intellia Therapeutics in Q4 2018 and held it in 14 quarters.
Geneos Wealth Management's Intellia Therapeutics position peaked at $191K in Q2 2021.
319 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2022.

Based on Geneos Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.